Last reviewed · How we verify
Fluticasone Evohaler
Fluticasone Evohaler is a Inhaled corticosteroid Small molecule drug developed by University of Dundee. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
Fluticasone is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release.
Fluticasone is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Fluticasone Evohaler |
|---|---|
| Sponsor | University of Dundee |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that acts as a glucocorticoid receptor agonist in airway tissues. It suppresses the production of inflammatory cytokines, chemokines, and adhesion molecules, reducing airway inflammation, mucus production, and bronchial hyperresponsiveness. The Evohaler is a metered-dose inhaler formulation designed for direct delivery to the lungs.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Hoarseness
- Tremor
- Headache
- Palpitations
Key clinical trials
- Efficacy of Intermittent Tiotropium in Early Childhood Wheezing (PHASE4)
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate (PHASE1)
- Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System (NA)
- FLuticasone in cOvid Treatment (FLOT) (PHASE2, PHASE3)
- Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients (NA)
- Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis (PHASE4)
- Fluticasone and Salmeterol in Allergic Rhinitis (PHASE4)
- Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Evohaler CI brief — competitive landscape report
- Fluticasone Evohaler updates RSS · CI watch RSS
- University of Dundee portfolio CI
Frequently asked questions about Fluticasone Evohaler
What is Fluticasone Evohaler?
How does Fluticasone Evohaler work?
What is Fluticasone Evohaler used for?
Who makes Fluticasone Evohaler?
What drug class is Fluticasone Evohaler in?
What development phase is Fluticasone Evohaler in?
What are the side effects of Fluticasone Evohaler?
What does Fluticasone Evohaler target?
Related
- Drug class: All Inhaled corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: University of Dundee — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing